



22 July 2021  
EMA/412895/2021  
Human Medicines Division

## Overview of (invented) names reviewed in June 2021 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 19-22 July 2021

	NRG meeting 16-17 Feb 2021		NRG meeting 20-21 Apr 2021		NRG meeting 26-27 May 2021		NRG meeting 29-30 Jun 2021		NRG meeting 16-17 Sep 2021		NRG meeting 09-10 Nov 2021		2021 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names*	73	33	33	36	24	31	38	34	0	0	0	0	<b>168</b>	<b>134</b>
Justification for retention of (invented) name **	3	3	2	7	2	0	1	6	0	0	0	0	<b>8</b>	<b>16</b>

\*Includes invented names, INN+MAH/TM and re-use applications.

\*\*In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



	NRG meeting 16-17 Feb 2021		NRG meeting 20-21 Apr 2021		NRG meeting 26-27 May 2021		NRG meeting 29-30 Jun 2021		NRG meeting 16-17 Sep 2021		NRG meeting 09-10 Nov 2021		2021 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Total number of objections raised	69	173	75	92	61	78	59	92	0	0	0	0	264	435
<b>Criterion - Safety concerns</b>														
Similarity with other (invented) name	46	119	61	68	45	55	37	70	0	0	0	0	189	312
Conveys misleading therapeutic/pharmaceutical connotations	1	0	1	1	0	0	2	2	0	0	0	0	4	3
Misleading with respect to composition	1	0	0	0	0	0	1	4	0	0	0	0	2	4
<b>Criterion - INN concerns</b>														
Similarity with INN	12	8	1	3	2	6	2	1	0	0	0	0	17	18
Inclusion of INN stem	0	0	0	1	0	1	0	0	0	0	0	0	0	2
<b>Criterion - Other public health concerns</b>														
Unacceptable qualifiers	2	0	2	0	0	2	8	0	0	0	0	0	12	2
Conveys a promotional message	3	4	3	1	2	5	8	2	0	0	0	0	16	12
Appears offensive or has an inappropriate connotation	1	2	2	0	5	1	0	1	0	0	0	0	8	4
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Similarity between name of prodrug and related active substance	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Others	3	40	6	22	7	8	1	12	0	0	0	0	17	82

See *Guideline on the [Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure \(EMA/CHMP/287710/2014\)](#)* for detailed explanations of criteria used.